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Abstract
To analyse current data on transmission of human cytomegalovirus (HCMV) via breast milk with subsequent symptomatic HCMV infec-
tion of the preterm infant and to report on long-term follow-up, a systematic literature review was performed using EMBASE, MED-
LINE and CINAHL (January 1966 to December 2008) Studies were included for analysis if congenital HCMV infection was excluded and
transmission via breast milk was either conﬁrmed or strongly suspected. Twenty-six studies were included for analysis. Maternal
HCMV-IgG-positivity was reported to be in the range 51.6–100% (median 81.6%), HCMV-IgG detection in breast milk in the range 67–
97.2% (median 80%) and HCMV-positivity of the infants in the range 5.7–58.6%. Symptomatic HCMV disease occurred in 0–34.5% (med-
ian 3.7%) and severe sepsis-like syndrome in 0–13.8% (median 0.7%). Data on long-term outcome of preterm infants with symptomatic
HCMV infection revealed a low risk for mild neurological and cognitive sequelae, without hearing impairment. Recommendations for
high-risk preterm infants diverged markedly. The current data report low rates of symptomatic disease after transmission of HCMV via
breast milk to the preterm infant without evidence of certain long-term sequelae. The results of our review do not support a general
approach, either by avoidance or pasteurization of breast milk, in high-risk preterm infants.
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Introduction
Human cytomegalovirus (HCMV) is an ubiquitous herpesvirus
that persists lifelong in monocytes and granulocytes [1]. A
typical sign of HCMV infection is so called ‘owl’s eye’ inclu-
sion bodies as a consequence of its cytopathogenic effect.
HCMV is excreted in saliva, urine and genital secretions for
months to years and is also found in breast milk, blood prod-
ucts and tissue- and organ-transplants [2]. Approximately
50% of adults are carriers of HCMV and therefore potential
sources of transmission [3]. In general, postpartum HCMV
infection in infants and children takes an asymptomatic
course. Symptomatic congenital disease may include intra-
uterine growth retardation, thrombocytopaenia, prematurity,
hepatosplenomegaly, ‘blueberry-mufﬁn-like’ rash, pneumonia,
intracranial calciﬁcations, microcephaly, jaundice, chorioretini-
tis, hearing loss and psychomotor retardation [2,3]. Diagnos-
tic methods include PCR technique, cell cultures and
detection of HCMV speciﬁc antibodies or intracellular viral
proteins [4,5]. Gancyclovir has proved to be effective in
infants with severe symptomatic congenital infection by
reducing hearing impairment during a 1-year follow-up [6].
Subsequent to the early 1970s, human breast milk has
been known as a potential source of HCMV infection, and
different transmission rates from the mother to the child
have been reported [7]. In 17of 63 HCMV positive women
(27%), HCMV was isolated from breast milk mainly within
the ﬁrst week postpartum (range 2 days to 10 weeks) [7]. In
a cross-sectional study, HCMV-infected breast milk was sug-
gested to be the most important source of HCMV infection
during the ﬁrst year of life (Stagno et al. 1980) [8]. In 1983,
signs of neutropaenia, lymphocytosis, thrombocytopenia and
symptoms of hepatosplenomegaly were associated with
HCMV disease in infants infected via breast milk [9]. In 1998,
high rates of very low birth weight infants were reported to
be at increased risk of symptomatic HCMV infection [10].
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Methods to prevent infection via breast milk in preterm
infants include heating and freezing procedures. Holder pas-
teurization (62.5C, 30 min) and short–term heating (72C,
5–10 s) are referred to as the most effective methods for
reducing the risk of HCMV transmission via breast milk [11–
15]. Although freezing procedures do not completely elimi-
nate the virus, these methods are found to be less harmful
to immunological factors contained in breast milk. Thus, dif-
ferent recommendations for breastfeeding the premature
born infant have been reported [16–21].
This review aims to elucidate current knowledge of
HCMV transmission via breast milk and to detail the possible
sequelae for the preterm infant.
Materials and Methods
The EMBASE, MEDLINE and CINAHL databases were
searched systematically to identify all papers published in the
English and German literature on the relationship between
CMV infection transmitted via breast milk and associated
sequelae, during the period January 1966 to December 2008.
For the search, the following keywords were utilized both
individually and in different combinations: infant-newborn
(Medical Subject Headings, MeSH), OR infant-premature
(MeSH), OR infant, low birth weight (MeSH), OR infant, very
low birth weight (MeSH), OR Infant-preterm (MeSH), OR
infant, premature (MeSH), OR infant, newborn (MeSH), OR
newborn (text word), OR infant (text word), OR neonate
(text word), OR premature birth (text word), cytomegalo-
virus (MeSH), OR epidemiology (MeSH), OR transmission
(MeSH), breast (MeSH), OR breastfeeding (MeSH), OR milk,
human (MeSH), OR breast milk (MeSH), OR human, milk
(MeSH), OR immunologic factors (text word), OR antiviral
factors (text word), outcome (MeSH), OR neurodevelop-
mental-outcome (MeSH), OR follow-up (MeSH).
Studies were included for analysis if congenital HCMV
infection was excluded and transmission via breast milk was
either conﬁrmed or strongly suspected. Reports on less than
ten infants were included and presented as case reports. A
diagnosis of HCMV infection had to be conﬁrmed by either
PCR or ELISA technique for HCMV-IgM and IgG in studies.
Premature birth was deﬁned as birth before completion of
37 weeks of gestation. Transmission via breast milk had to
be conﬁrmed or strongly suspected in studies.
Data were evaluated according to the rate of transmission
of HCMV from the mother to the premature born infant dur-
ing lactation, seroprevalence of mothers, detection of HCMV
in breast milk (rate and time of conversion during lactation),
methods of HCMV detection, seroreactivity of HCMV in the
infants (rate and time of detection in the newborn), risk of
acquiring disease in the newborn, and symptoms and signs of
the infants’ disease. In addition, short-term and long-term
sequelae of HCMV disease in the infants were evaluated.
Results
In total, 26 studies eligible for inclusion were identiﬁed
[9,10,22–45]. Twenty studies [9,10,22–39] and four case
reports [40–43] evaluated clinical manifestations of HCMV
disease in the preterm infant. Five studies reported long-
term sequelae of HCMV disease [29,30,34,42,44]. One study
evaluated virus secretion in preterm infants [45]. Twelve
studies used PCR and seven used HCMV serology for
HCMV detection. Additionally, viral cultures were used in 14
out of 16 studies [10,22,23,25–27,29–31,34–37,39]. Eight
studies showed data concerning the detection of HCMV in
breast milk [10,22,23,25,26,28,30,37] and six studies docu-
mented the time of HCMV detection in breast milk
[10,22,23,28,30,37].
All studies included were prospective [10,22,23,25–32,34–
37,39]. HCMV-IgG seroprevalence of mothers was reported
to be in the range 52–97%, HCMV-positivity of infants was
reported to be in the range 5.7–58.6%. HCMV was detected
in breast milk of 66–96% (median 87%) of HCMV-IgG posi-
tive mothers. The time of ﬁrst detection of HCMV in breast
milk was in the range 8–119 days. Five studies reported
HCMV detection within the ﬁrst 2 weeks after birth
[22,23,28,30,37], one study reported HCMV detection later
than 2 weeks postpartum [10], and ten studies did not
report the exact time of detection. Study design, inclusion
criteria, methods, rate and time of HCMV detection in
breast milk and infants of 16 studies providing the required
information completely or in part are summarized in
Tables 1 and 2 [10,22,23,25–32,34–37,39]. The features
found in HCMV-positive infants with breast milk-acquired
infection included: sepsis-like symptoms, hepatopathy, he-
patosplenomegaly, hepatitis, thrombocytopaenia, neutropae-
nia, myoclonia, petechiae, respiratory distress syndrome,
hyperbilirubinaemia, bradycardia, apnoea, cholestasis, jaun-
dice, extended bowel, grey pallor, elevation of liver enzymes,
pneumonitis, lymphadenopathy, maculopapular rash.
The main features and reported frequencies in 25 studies
are shown in Fig. 1.
HCMV transmission to the preterm infant varied in the
range 5.6–58.6% (median 20%). The risk of symptomatic dis-
ease in the preterm infant was in the range 0–34.5% (mean
3.7%). Sepsis-like signs in preterm infants were observed in
0–13.8% (mean 0.7%); the data are summarized in Table 3.
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Five studies were excluded from the ﬁnal analysis because
they did not ﬁt the inclusion criteria or contained insufﬁcient
data for ﬁnal analysis. The study by Dworsky et al. 1983 [46]
had to be excluded because data on preterm infants were
not reported separately. The authors included 58 mother–
infant pairs of term and preterm infants, aiming to compare
rates of HCMV shedding into saliva, urine, genital secretions
and breast milk in postpartum women with rates of acquisi-
tion of infection by their infants. None of the infants born to
seronegative mothers became infected during the study
period in contrast to 12 infants (30%) born to 41 seroposi-
tive mothers, who became infected between birth and
8 months of age. Infants who breastfed for longer than
1 month became infected more often (p 0.15). Two of 13
preterm infants (15.4%) developed symptomatic disease
(pneumonitis), which resolved. Long-term sequelae such as
TABLE 2. Methods, rates and time of human cytomegalovirus detection in breast milk and the preterm infant of 16 studies
[10,22,23,25–32,34–37,39]
Breast milk Infants
Methods Rate (%) Time (days) Methods Time (days) References
PCR, culture 85 £56 PCR, culture £56 (29%)
>56 weeks (71%)
[10]
PCR, culture 88 8–119 PCR, culture, serologya 30–85 [22]
PCR, culture 93.6 10c (virus)
3.5c (DNA)
PCR, culture 28–69 (mean 42) [23]
PCR, culture 67 – PCR, culture Median 34.2 [25]
PCR, culture 68 – PCR, culture 7–83 (median 25) [26]
– – – Culture 62 [27]
PCR 87.5 £14 (94%)
>14 (6%)
PCR 28–96 [28]
PCR, culture – – PCR, culture, serologyb 23–190 [29]
PCR, culture 97.2 12.3d ± 9.4 Culture, serology 21–168 (mean 77) [30]
– – – Culture, serology 27–120 (median 63) [31]
– – – PCR, enzyme immunoassay 32–140 (median 75) [32]
– – – PCR, culture 21–56 [34]
- – – Culture, serology 48–72 [35]
PCR, culture, serology – – PCR, culture, serology Median 45.5 [36]
PCR, culture 80 £14 PCR, culture 34 and 46 (two cases) [37]
– – – PCR, culture, serology 43–89 (median 73) [39]
aCord and venous blood at birth.
bCord blood.
cMedian.
dMean.
TABLE 1. Study design and inclusion criteria of 16 studies providing data on human cytomegalovirus transmission rates via
breast milk to the preterm infant [10,22,23,25–32,34–37,39]
Year Study design Population GA/BW
Number
of
mothers
Number
of infants
Study
period
(years) References
1998 Prospective Preterm infants <32 weeks or <1500 g 56 67 1 [10]
1997 Prospective case study Suspected disease (56%), Screening (44%) <32 weeks or <1500 g 15 16 1.6 [22]
2001 Prospective, case–control study Preterm infants and their mothers and
matched controls
<32 weeks or <1500 g 151 170 3 [23]
2001 Prosp. Preterm infants and their mothers <34 weeks 24 31 0.5 [25]
2002 Prospective Preterm infants and their mothers <34 weeks 41 54 1 [26]
2002 Prospective Preterm infants and their mothers <32 weeks 38 40 1 [27]
2003 Prosp. Preterm infants and their mothers <34 w or <2000 g 30 43 1 [28]
2004 Prosp., case control study Preterm infants infected via breast milk <32 w or <1500 g – 22 3 [29]
2004 Prosp., case control study Breastfed preterm infants <35 w or <1500 g 38 42 2 [30]
2004 Prosp. Infants admitted to NICU, screened by
symptoms
24-38 w 705-2220 g – 16 5 [31]
2004 Prosp. Preterm infants and their mothers <34 w or <1500 g 121 127 1 [32]
2005 Prosp., case control study Breastfed and formula fed preterm infants
of HCMV+/) mothers
<32 w or <1500 g 77 96 3 [34]
2005 Prosp. Very low birth weight preterm infants £1000 g 101 119 1.1 [35]
2006 Prosp., case control study Preterm infants with HCM-viruria during
hospital stay
£30 or <1000 g – 40 of 463
infants
8.5 [36]
2007 Prosp. case study Preterm infants and their mothers 24 + 2 to 27 + 5 w 6 10 0.25 [37]
2008 Prosp., case control study Preterm infants and their mothers £31 w 48 58 2 [39]
GA, gestational age; BW, body weight.
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sensoryneural hearing loss did not occur during the study
period. The study by Granstro¨m et al. [47] was excluded
because almost all the children were born at full term, and
transmission via breast milk was not conﬁrmed. Kumar et al.
[48] reported on a low number of infants infected postna-
tally, and transmission via breast milk could only be assumed.
In a study by Kumar et al. [49], no association of HCMV
transmission with breastfeeding was documented and Whitley
et al. [50] reported on formula-fed infants acquiring HCMV
in early infancy.
Long-term outcome
Five studies reported on long-term outcome of HCMV infec-
tion transmitted via breast milk in preterm infants
[8,29,30,34,44].
Chronic excretion of HCMV in urine and saliva was found
to persist in infected infants for over 2 years [8,29]. By
contrast to congenital HCMV infection, no association with
sensoryneural hearing loss has been documented
[29,30,34,44]. Regarding neurological status, motor develop-
ment and development of speech, no signiﬁcant differences
were found between HCMV-infected infants and controls
[29,30,34]. Only one study reported severe neurological
sequelae in infants with perinatally acquired HCMV infection
and onset of excretion during the ﬁrst 2 months of life [44].
Later HCMV acquisition was not associated with neurological
sequelae. However, the number of infants who acquired
HCMV via breast milk was not clearly deﬁned.
The following studies did not match the inclusion criteria
but provide additional information on early postnatally
acquired HCMV infection. In 13 of 46 HCMV positive infants
(28.3%), who were followed-up at 2 years of age, a poor per-
formance of speech (Denver Development Screening Test)
and, in two children (4.4%), a mild developmental retardation
were observed (Granstro¨m 1979 [47]). Tests regarding gross
and ﬁne motor skills did not show any signiﬁcant differences
from healthy infants. Ten infants with postnatally acquired
HCMV infection were followed-up at 4.5–10.7 years of age by
Kumar et al. 1984 [48]. The mean WISC-R intelligence quo-
tient (Weschler Intelligence Scales for Children) for postna-
tally infected infants was 89.0 and correlated well with
maternal IQ (84.5). No hearing abnormalities were found. In
another study by Kumar et al. 1984 [49] 21 infants with post-
natally acquired HCMV infection, who were followed during
the ﬁrst 12 months of life, showed a mean IQ of 107, which
did not differ signiﬁcantly from that of non-infected controls
(IQ 102). Neither study provided information on prematurity.
The study by Peckham et al. 1987 [45] revealed virus secretion
up to 36 months of age without data on neurodevelopmental
outcome of the children.
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FIG. 1. Number of studies reporting on main symptoms of infants
with human cytomegalovirus infection via breast [9,10,22–43].
TABLE 3. Data from 12 studies reporting on human cytomegalovirus (HCMV) seropositive mothers, number (%) of
HCMV positive infants, number (%) of infants with symptomatic and severe disease (sepsis-like syndrome)
[10,23,25–28,30,32,34,35,37,39]
Mother HCMV+ Breastfed infants HCMV+ infants % Symptomatic infants % Severe disease % References
29 29 17 58.6 10 34.5 4 13.8 [10]
78 87 33 37.9 16 18.4 4 4.6 [23]
24 20 5 25 0 0 0 0 [25]
41 33 13 39.4 3 23.1 1 7.7 [26]
28 18 1 5.6 0 0 0 0 [27]
24 30 3 10 0 0 0 0 [28]
36 40 6 15 5 12.5 5 12.5 [30]
121 49 13 26.5 0 0 0 0 [32]
72 70 4 5.7 1 1.4 1 1.4 [34]
56 61 4 6.6 1 1.6 1 1.6 [35]
5 7 2 28.6 1 14.3 0 0 [37]
29 35 5 14.3 2 5.7 0 0 [39]
Mean (median) 22.8 (20) 9.3 (3.7) 3.5 (0.7)
HCMV+, HCMV positive.
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Discussion
The present review has revealed HCMV transmission via
breast milk in 66–96% of HCMV-IgG positive mothers with
subsequent HCMV-positivity of the infants in the range 5.7–
58.6%. Median rates of symptomatic HCMV disease were
3.7% in HCMV positive infants, with rates of 0.7% for severe
sepsis-like syndrome. Rates of infection and disease vary
greatly from study to study, probably reﬂecting differences in
study design, different incidence rates of HCMV positive
mothers and different inclusion criteria for preterm infants
according to either gestational age or birth weight (e.g. pre-
term infants below 32 or 34 weeks or up to 38 weeks of
gestation or infants below 1000 or 1500 g), highlighting the
urgent need for a prospective multicentre study to address
these questions. According to the few data concerning long-
term outcome in preterm infants with overt HCMV infec-
tion, a low risk of mild neurological and cognitive sequelae
without hearing impairment was suggested.
Symptomatic HCMV infection via breast milk does not
usually occur in full-term infants because of the transmission
of protective maternal antibodies, starting within the 29th
gestational week [19,51]. In very premature born infants, this
transmission of maternal antibodies is missing, which puts
them at high risk for symptomatic HCMV infection transmit-
ted via breast milk [51,52]. Low birth weight and an early
postnatal transmission are risk factors for symptomatic and
even severe infection [18,53]. HCMV transmission via human
milk might be a cofactor aggravating the clinical course of
pre-existing pulmonary, haematological or hepatic conditions
in certain preterm infants, although it is unlikely to cause
symptoms in healthy preterm infants [38,54]. However, pri-
mary HCMV infection even creates the possibility of HCMV
pneumonitis in full-term born infants [51]. Sequelae of
HCMV infection transmitted via breast milk within the ﬁrst
2 months of life are difﬁcult to separate from complications
of premature birth [19]. Data on long-term sequelae are
scarce, suggesting no sensoryneural hearing loss and only
minor effects on neuromotor development [18,51].
Pasteurization is very effective in inactivating HCMV in
breast milk, but also decreases the protective factors in breast
milk [18,19,51]. Freezing procedures preserve the protective
factors but are not effective in inactivating HCMV [18,19,51].
However, breast milk has several advantages and possibly pro-
vides long-term protection [19,20,55]. The issues raised by
Willeitner in 2004 [54] regarding whether mothers of infants
at risk who intend to breastfeed should be tested for HCMV-
IgG status and whether the disadvantages of pasteurization
outweigh the risks of contracting HCMV are still debated.
There is little consensus among paediatricians and neona-
tologists on the approach to the prevention and management
of HCMV infection acquired via breast milk in preterm
infants. The issue has been raised by a series of reports from
investigators in Tu¨bingen, Germany, as reported in detail by
Schleiss [56] Currently, there are few national recommenda-
tions on handling the breast milk of HCMV-IgG positive
mothers. The American Academy of Pediatrics [17] recom-
mends human milk for preterm and other high-risk infants
either by direct breastfeeding or using the mothers own
expressed milk. Banked pasteurized human milk is suggested
to be a suitable feeding alternative. Decisions about breast-
feeding of very low birth weight infants by mothers known
to be HCMV-seropositive should be made with caution,
weighing the potential beneﬁts of human milk versus the risk
of HCMV transmission. The Committee for Nutrition of the
Austrian Society of Paediatrics and Adolescent Medicine [16]
recommends determining the HCMV serostatus of every
mother and, in the case of HCMV-IgG-positivity, the colos-
trum has to be abandoned and breast milk has to be pas-
teurized before being fed. This procedure is suggested for
the infant up to the corrected gestational age of 35 weeks.
The French Society for the Safety of Nutrition [18] restricts
the feeding of raw breast milk to preterm infants above
32 weeks of gestation (above 1500 g). The guidelines of the
Swedish National Board of Health and Welfare recommend
the freezing of HCMV positive maternal milk for preterm
babies <32 weeks of gestation [57].
Interestingly, approximately 30 years ago, Stagno et al.
[8] and, more recently, Stronati et al. [58] summarized this
mode of HCMV transmission via breastfeeding as a form
of passive/active immunization. In most cases, the infection
occurs in the presence of speciﬁc anti-CMV antibodies and
despite the presence of immunoglobulins, macrophages,
neutrophils and lymphocytes in breast milk, which should
ensure both a speciﬁc and a nonspeciﬁc antiviral defence.
In view of the biological and nutritional value of breast-
feeding, this transmission route should be interpreted as a
positive factor [58]. Three decades later, we still share the
view of Stagno et al. [8] that the minimal risk associated
with the transmission of HCMV through breast milk
is clearly outweighed by the well-established value of
breastfeeding.
Summarizing the results of our review, the mean rate of
HCMV transmission was 22.8%, the mean risk of symptom-
atic disease was 3.7%, and that of sepsis-like symptoms was
0.7%. The question remaining is whether the low risk of
severe symptomatic disease justiﬁes withholding colostrum
and breast milk feeding from all preterm infants below
32 weeks of gestation. Do we trade the beneﬁts of human
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milk for the slight chance of ‘clinical deterioration’ [59]? In
our opinion, an individual decision, based on the health sta-
tus of the preterm infant, should be preferred to a general
approach.
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